Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q2 2024 Earnings Presentation
22 slides from Oncoinvent Asa's earnings presentation, Aug 21, 2024
Slide 1: Advancing selective AXL inhibition in STK11m Non-Squamous NSCLC
Advancing selective AXL inhibition in STK11m Non-Squamous NSCLC Q2 2024 presentation
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation or forecasts will come to pass or that any forecast result constitute forward-looking statements. Forward-looking will be achieved, and you are cautioned not to place any statements are statements that are not historical fa
Slide 3: Highlights: Solid clinical & financial progress
Highlights: Solid clinical & financial progress • Advancement of BGBC016 study in 1L Non-Squamous NSCLC STK11m: o Completion of enrollment in all three cohorts of Ph1b part (75mg, 100mg and 150mg) o Initiated 2 nd dose of 150 mg in Ph2a part after positive recommendation from independent Data Safety
Slide 4: 1L STK11m Non-Squamous NSCLC: A Significant Opportunity
1L STK11m Non-Squamous NSCLC: A Significant Opportunity 4
Slide 5: Our focus area: a substantial, growing market
Our focus area: a substantial, growing market Global Oncology Pharmaceuticals Spending, 2019 to 2028 ($Billions) 9.9% +$154BN CAGR 2024–2028 NET NEW GROWTH IN NEXT FIVE YEARS $409 $378 $344 $299 $255 $223 $188 $198 $166 $148 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 5 Source: IQVIA Institute
Slide 6: NSCLC contributes a significant share of spending
NSCLC contributes a significant share of spending Global Oncology Spending by Tumor Type, 2019 to 2028 ($Billions) NSCLC 6 Sourced from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2024
Slide 7: Our product portfolio fits several growth areas
Our product portfolio fits several growth areas Top Growth Areas Identified by Stiefel Oncology Market Update June 2024 Cell Therapies Bemcentinib s Targets STK11m gic P r ra p i Th ec olo e isi es Bi on IO In Im es na nity at m ug te u Bemcentinib BGB Participates nj Addresses Innate Co T-Cell Thro
Slide 8: Bemcentinib expected to address highest unmet needs
Bemcentinib expected to address highest unmet needs Current Treatment Practices: 1L Non-Squamous NSCLC 1. PD-L1 levels predicts response to Immunotherapy 2. Mutational status predicts response to Targeted Therapies ~31,000 pts per year** 2% 2% 3% 5% Currently 5% ALK Mutations Actionable MET Other Wi
Slide 9: Large potential in >30,000 US/EU 1L STK11m NSCLC
Large potential in >30,000 US/EU 1L STK11m NSCLC 1L NS* NSCLC 31,620 pts STK11m Pts 30,400 pts - Actionable Mutations x Average x 14,300 USD Monthly Price x 10 mos. x Average . Mos. Treatment 9 ~4.3 Billion USD/Year *Non-Squamous Source: Company estimates
Slide 10: The case for AXL inhibition with bemcentinib in 1L STK11m NSCLC
The case for AXL inhibition with bemcentinib in 1L STK11m NSCLC 10
Slide 11: Bemcentinib: highly differentiated AXL inhibitor
Bemcentinib: highly differentiated AXL inhibitor Selective, potent – improved AXL inhibition with fewer side effects Concentrates in lung (40x); crosses blood-brain barrier Extensive safety data base: studied in over 600 patients Monotherapy activity seen in multiple indications Proven combinations
Slide 12: Strong rationale for AXL inhibition in STK11m pts
Strong rationale for AXL inhibition in STK11m pts Immunosuppressed AXL Inhibition Restores Immunoresponsive Tumor STK11m Tumor Immune Response Presence of CD8+ T cells CD8+ T cell exclusion Presence of CD8+ T cells High PDL-1 expression Low/No PDL-1 expression Stimulatory dendritic cells Stimulatory
Slide 13: 2nd dose initiated as planned in Ph2A of BGBC016
2nd dose initiated as planned in Ph2A of BGBC016 Ph1b – 3 doses studied Ph1b/2a Overlapping Protocol First dose moved into Ph2a Second dose moved into Ph2a Ph1b (US) Dose Escalation Ph2a (US & EU) Expansion Study Phase 3 doses Up to 2 doses 1L Advanced/Metastatic NS-NSCLC pts 40 1L STK11m NS-NSCLC p
Slide 14: Ground-breaking agreement with Tempus AI (BGBC016)
Ground-breaking agreement with Tempus AI (BGBC016) “Matching” 6 Million Patient Outcomes Data Contextual Patients Genomic Database Collected for Comparison Identified in Tempus “Matching” Pts Arm Created Database provides “bespoke” Same characteristics Tempus’ Network of Tempus identifies pt dataset
Slide 15: Most advanced AXL inhibitor in development for STK11m
Most advanced AXL inhibitor in development for STK11m Specific to Company/MoA Current Phase* Specific to 1L? NSCLC Population STK11m pts? BGB/AXL inhibitor + anti-PD1+ Ph 1b/2a STK11m chemo STK11m, KEAP-1m, AZ/anti-PD1+anti-CTLA4 Ph 3b KRASm Regeneron/anti-IL6R + anti-PD1 Ph 1b 1L – 4L STK11m or EGF
Slide 16: Highly promising and differentiated treatment for 1L STK11m Non-Sq. NSCLC
Highly promising and differentiated treatment for 1L STK11m Non-Sq. NSCLC • STK11m patients now seen as a major underserved lung cancer patient population that requires new immuno-oncology approaches • AXL expression is a key driver of resistance to CPI and chemo in STK11m patients • STK11m patients
Slide 17: Activities in lung cancer extended into new combination
Activities in lung cancer extended into new combination • Trial led by Josephine Taverna, M.D., Assistant Professor, The University of Texas Health Science Center at San Antonio, in collaboration with BGB and Sobi® • Ph1b/2 Investigator-led trial combining bemcentinib + pacritinib (VONJO® marketed b
Slide 18: Key financials and newsflow
Key financials and newsflow 18
Slide 19: Key financials Q2 2024
Key financials Q2 2024 Stable cash use and strengthened (NOK million) Q2 2024 Q2 2023 YTD 2024 YTD 2023 FY 2023 Operating revenues 0.0 0.0 0.2 0.0 0.4 financial position Operating expenses 50.8 47.8 90.7 120.2 192.2 Operating profit (-loss) (50.8) (47.8) (90.5) (120.2) (191.8) • Secured NOK 138.9 M
Slide 20: Newsflow expected in H2 2024 - H1 2025
Newsflow expected in H2 2024 - H1 2025 H2 2024 H1 2025 ü Complete enrollment of Ph1b • Regulatory guidance on pivotal development path in ü 2nd dose initiated in Ph2a 1L STK11m NSCLC ü Establish synthetic control arm • Complete enrollment of Ph2a • First patient in NIH funded lung cancer trial • Upd
Slide 21: Clear focus to unlock significant value potential
Clear focus to unlock significant value potential • Focused approach in 1L STK11m NSCLC with bemcentinib + standard of care • Phase 1b showed acceptable safety of combination • Phase 2a on plan, second and final dose initiated • Collaboration with Tempus AI provides relevant and innovative contextua
Slide 22: Address, Phone Number, E-mail
A d d re s s Mo l l e n d a l s b a k ke n 9 , 5 0 0 9 B e rg e n , N o r way P h o n e Nu mb e r + 47 559 61 159 E - ma i l p o s t @b e rg e n b i o . co m 22